RCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI

Allergy TherapeuticsAnnouncement

31/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe5401Qa&default-theme=true

RNS Number : 5401Q  Allergy Therapeutics PLC  31 May 2024

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Group")

 

 

Allergy Therapeutics presents scientific findings from research portfolio at
EAACI 2024

 

31 May 2024 Allergy Therapeutics plc (AIM: AGY), the integrated commercial
biotechnology company specialising in allergy vaccines, today announces that
it will be sharing key scientific findings from across its research portfolio
at the European Academy of Allergy and Clinical Immunology (EAACI) Congress
(https://eaaci.org/agenda/eaaci-congress-2024/) , taking place from today
until 3 June 2024 in Valencia, Spain.

 

The EAACI Congress is the world's largest scientific conference that
specialises in the field of allergy and clinical immunology and the flagship
meeting of the European Academy of Allergy and Clinical Immunology, an
association of more than 16,000 clinicians, researchers and allied health
professionals from 124 countries, dedicated to improving the health of people
affected by allergic diseases.

 

Among its 12 posters being presented, Allergy Therapeutics will share:

·      The positive results from the pivotal Phase III G306 trial, which
evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course
subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to
address the cause of symptoms of allergic rhinoconjunctivitis due to grass
pollen. The trial successfully met its primary endpoint, as previously
announced on 14 November 2023. The findings from the G306 trial, alongside
results of the earlier G309 exploratory field study, will support the Group's
marketing authorisation application (MAA), with a planned submission in Q4
2024.

·      Results from analysis of patient and caregiver preferences for
different venom and pollen immunotherapy approaches and their implications on
adherence and treatment acceptance.

·      The beneficial safety and tolerability results from the healthy
subject subcutaneous dosing cohorts of the Phase I/IIa PROTECT trial of the
Group's novel virus-like-particle (VLP)-based peanut allergy vaccine candidate
("VLP Peanut"), without any major safety or tolerability findings. This
ongoing trial progressed in March 2024 to subcutaneous dosing of peanut
allergic patients, marking the start of the clinical proof of concept phase
using biomarkers to assess preliminary efficacy.

 

Allergy Therapeutics will also be hosting a symposium, "Setting a new standard
for grass subcutaneous immunotherapy," on Sunday, 2 June, 13:45-14:45 CEST,
chaired by Professor Dr. Stefan Zielen, Head of the Institute for Respiratory
Medicine, Frankfurt, Germany. The symposium will include presentations
covering regulatory and clinical challenges in allergen immunotherapy trials,
as well as results from the Group's pivotal Phase III G306 trial of Grass MATA
MPL by key experts from the US and EU.

 

In addition, Prof. Mohamed Shamji from Imperial College, London and EAACI Vice
President Congresses, will showcase the Group's scientific adaptive approaches
to clinical development, as applied in the successful G309 and G306 studies,
as examples of current state-of-the-art clinical development in a plenary
session.

 

Finally, Prof. Shamji will host an embargo session at the closure day of the
EAACI conference to release the Group's recently accepted VLP Peanut paper in
the peer reviewed Journal of Allergy and Clinical Immunology, the official
publication of the American Academy of Allergy, Asthma, and Immunology
(AAAAI). This session will highlight the promising biomarker safety and
efficacy profile of VLP Peanut, including the first clinical results
supporting the hypo-allergic profile of VLP Peanut based on the skin test
results from the PROTECT Phase I/IIa study.

 

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "At
Allergy Therapeutics, our mission is to transform lives by breaking new ground
in immunology treatments, and we are thrilled to have such a robust presence
at this year's EAACI Congress. The research we are sharing demonstrates the
strength of our science and, with one innovative short-course allergy
immunotherapy targeting peanut allergy currently in the clinic and another
targeting grass pollen allergy progressing towards a planned market
authorisation application, we are steadfast in our commitment to helping
patients change the way they think about their allergies and better manage
their conditions."

 

The complete list of Allergy Therapeutics-sponsored abstracts accepted by
EAACI for presentation are available on the Group's website.

 

No new material price sensitive information is expected to be disclosed on
Allergy Therapeutics at the EAACI Congress 2024.

 

 

 

 Allergy Therapeutics' Symposium

 Setting a new standard for grass subcutaneous immunotherapy

 Sunday, 02 June; 13:45-14:45 (CEST)
 Introduction                                                                   Welcome and introduction

 Chair: Professor Dr. Stefan Zielen, Head of the Institute for Respiratory
 Medicine, Frankfurt, Germany
 Speaker                                                                        The journey to registration: Challenges for allergen immunotherapy trials

 Professor Dr. med. Markus Ollert, Director of the Department of Infection
 & Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
 Speaker                                                                        Challenge accepted: Results from the pivotal Grass Phase III clinical trial

 Dr. Lawrence DuBuske, Clinical Professor of Medicine, George Washington
 University School of Medicine, Washington, DC, United States
                                                                                Q&A session

 All Speakers

 

 

ENDS

 

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Freddy Crossley, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGFKVGZGDZM